Recently, two cases of T-cell large granular lymphocytic (T-LGL) leukaemia were described, which occurred 4-6 weeks after autologous haematopoietic stem cell transplantation (HSCT). 1, 2 In both cases, the only immunosuppression was the high-dose chemotherapy used during conditioning. Less than 30 days elapsed between engraftment and detection of leukaemia, a period too brief for any known process of leukaemogenesis. Finally, Epstein-Barr virus (EBV) infection was not found in either. These features are very different from post transplantation lymphoproliferative diseases (PTLD) after allogeneic HSCT, where typically, prolonged periods of immunosuppression necessitated by graft-versus-host disease (GVHD) lead to unchecked reactivation of EBV, causing the abnormal proliferation of B cells opportunistically infected with EBV. 3 For these reasons, it would be implausible to classify these two cases of T-LGL leukaemia as PTLD after autologous HSCT.
A more likely explanation is the existence of a clonal T-cell proliferation undetected before autologous HSCT. The conditioning chemotherapy might be relevant, in leading to a period of decreased immunosurveillance, which allowed proliferation of the neoplastic T cells. Alternatively, more frequent examination of the peripheral blood after HSCT might have led to the diagnosis of this pre-existing disorder. It must be noted that neither report gave details of the blood counts or marrow immediately before HSCT.
1,2 Furthermore, the detection of clonal rearrangement of the T-cell receptor (TCR) gene should have enabled clonal-specific polymerase chain reaction (PCR) primers to be designed. These primers could then have been used to define if the neoplastic T-cell clone existed pre-HSCT. This has also not been done. Therefore the de novo development of T-LGL leukaemia as a PTLD after autologous HSCT remains unconfirmed.
On the other hand, abnormal proliferation of T-LGL has been well documented after allogeneic HSCT. T-LGL expansion occurs within 3-15 months post-HSCT. Most cases are polyclonal or oligoclonal. A relationship between viral infections, particularly with cytomegalovirus, has been postulated. 4, 5 Although T-LGL expansion after allogeneic HSCT is usually asymptomatic, autoimmune manifestations and mild to severe haematopoietic suppression have been reported. 5 Owing to their reactive nature, T-LGL expansions are usually self-limiting. Interestingly, an association with a lower rate of disease relapse has been observed. 4, 5 Clonal T-LGL leukaemia after allogeneic HSCT has also been reported. 6 In this case, T-LGL leukaemia developed 3 months after allogeneic HSCT. Similar to conventional B-cell PTLD, intense immunosuppression administered for GVHD preceded leukaemia, and the leukaemic cells were donor in origin. However, EBV infection was not demonstrable. These features suggested the case to be a genuine EBV-negative PTLD, 7 an entity increasingly recognized after solid organ allografting.
The diagnosis of T-LGL leukaemia is not easy.
LGLs are sometimes small in size, and the detection of cytoplasmic azurophilic granules requires high-power microscopic examination by experienced haematopathologists. Furthermore, although an LGL lymphocytosis of 42 Â 10 9 /l is typical, in cases where the count is o2 Â 10 9 /l, a diagnosis of T-LGL leukaemia is still appropriate if T-cell clonality can be demonstrated. 8 For these reasons, T-LGL leukaemia may be missed in routine pathology laboratories. In relating the development of T-LGL expansions or leukaemia to HSCT, a careful morphological, immunophenotypical and molecular evaluation of the peripheral blood and marrow should be undertaken before HSCT to exclude a pre-existing T-LGL disorder. In allogeneic HSCT, the origin of the T-LGL proliferation post-HSCT should be further defined.
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